TW200509925A - Method comprising irinotecan for treatment of breast cancer - Google Patents

Method comprising irinotecan for treatment of breast cancer

Info

Publication number
TW200509925A
TW200509925A TW093111614A TW93111614A TW200509925A TW 200509925 A TW200509925 A TW 200509925A TW 093111614 A TW093111614 A TW 093111614A TW 93111614 A TW93111614 A TW 93111614A TW 200509925 A TW200509925 A TW 200509925A
Authority
TW
Taiwan
Prior art keywords
irinotecan
breast cancer
treatment
fluoropyrimidine
anthracycline
Prior art date
Application number
TW093111614A
Other languages
English (en)
Inventor
Langdon L Miller
David Emanuel
James Patrick Mcgovren
Larry J Schaaf
Sumant Ramachandra
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of TW200509925A publication Critical patent/TW200509925A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093111614A 2003-04-28 2004-04-26 Method comprising irinotecan for treatment of breast cancer TW200509925A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46622203P 2003-04-28 2003-04-28

Publications (1)

Publication Number Publication Date
TW200509925A true TW200509925A (en) 2005-03-16

Family

ID=33418353

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093111614A TW200509925A (en) 2003-04-28 2004-04-26 Method comprising irinotecan for treatment of breast cancer

Country Status (13)

Country Link
US (1) US20040266704A1 (zh)
EP (1) EP1620099A1 (zh)
JP (1) JP2006524678A (zh)
KR (1) KR20050116166A (zh)
CN (1) CN1774249A (zh)
AU (1) AU2004233743A1 (zh)
BR (1) BRPI0409870A (zh)
CA (1) CA2523152A1 (zh)
CL (1) CL2004000888A1 (zh)
MX (1) MXPA05011568A (zh)
TW (1) TW200509925A (zh)
WO (1) WO2004096223A1 (zh)
ZA (1) ZA200508696B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107456456A (zh) * 2016-06-03 2017-12-12 江苏恒瑞医药股份有限公司 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
AU780454B2 (en) * 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death

Also Published As

Publication number Publication date
ZA200508696B (en) 2006-07-26
CA2523152A1 (en) 2004-11-11
US20040266704A1 (en) 2004-12-30
WO2004096223A1 (en) 2004-11-11
BRPI0409870A (pt) 2006-05-16
CN1774249A (zh) 2006-05-17
MXPA05011568A (es) 2005-12-14
CL2004000888A1 (es) 2005-03-18
AU2004233743A1 (en) 2004-11-11
JP2006524678A (ja) 2006-11-02
EP1620099A1 (en) 2006-02-01
KR20050116166A (ko) 2005-12-09

Similar Documents

Publication Publication Date Title
PL1913947T3 (pl) Terapia skojarzona do leczenia raka
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
MX2007003795A (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2009067397A3 (en) Treatment for solid tumors
WO2003103585A3 (en) METHODS OF TREATING ANGIOGENESIS, TUMOR GROWTH AND METASTASES
TW201129380A (en) Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2007126787A3 (en) Reagents and methods for cancer treatment and prevention
TW200509925A (en) Method comprising irinotecan for treatment of breast cancer
DE602005026510D1 (en) Anthracyclinderivate
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
WO2008060381A3 (en) Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.